EXCERPT

George Town, Cayman Islands, February 06, 2025 –(PR.com)– Legacy Pharma Inc. SEZC (“Legacy Pharma” or the “Company”), a specialty pharmaceutical company, announced the completion of the acquisition of InterMune, Inc. (“InterMune”) and the intellectual property rights to Esbriet® (pirfenidone) in the United States from Genentech, ​a member of the Roche Group​. This strategic acquisition underscores Legacy Pharma’s commitment to expanding its portfolio of high-quality pharmaceutical products and enhancing patient access to innovative treatments.

Esbriet®, a medication used to treat idiopathic pulmonary fibrosis (IPF), has shown significant promise in improving the lives of patients with this chronic and life-threatening lung disease. With this acquisition, Legacy Pharma aims to ensure the continued availability and distribution of Esbriet® to patients​ ​across the United States.​ Genentech will continue to provide access to Esbriet® in the United States until the completion of the business transfer. Furthermore, Roche will retain commercial rights in all other territories.​

Read full news release here.